Novartis Pharmaceuticals Corporation – FDA 483, Aug 8, 2024
Novartis Pharmaceuticals Corporation in Morris Plains, NJ, was cited for significant deficiencies in its manufacturing processes for sterile drug products, particularly Kymriah®. The inspection revealed issues with microbiological contamination prevention, inadequate laboratory controls for foreign particulates, and failures in quality control unit procedures regarding change control and batch record review. Additionally, the firm lacked appropriate computer system controls, indicating a broad range of compliance concerns.
ID · 44e0cb23-0ec8-4334-bb8c-6f66a38965a7
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.